Update shared on04 Sep 2025
With key metrics such as future P/E (16.49x) and net profit margin (54.67%) remaining stable, Camurus’s fair value assessment is unchanged, with the consensus analyst price target holding steady at SEK832.17.
What's in the News
- Camurus received UK MHRA marketing authorization for Oczyesa® (octreotide subcutaneous depot) for maintenance treatment of adult acromegaly patients, following comprehensive clinical studies including two Phase 3 trials.
- The European Commission granted marketing authorization for Oczyesa® in the EU for acromegaly patients, with studies showing significant improvement in IGF-1 normalization and sustained symptom reduction over 52 weeks.
- Topline 12-month Phase 2b POSITANO study results showed CAM2029 (octreotide SC depot) achieved an 8.7% relative reduction in total liver cyst volume in polycystic liver disease (PLD) patients, with improvements in symptoms and no unexpected safety issues; the product has Orphan Drug Designation in the US and EU.
Valuation Changes
Summary of Valuation Changes for Camurus
- The Consensus Analyst Price Target remained effectively unchanged, at SEK832.17.
- The Future P/E for Camurus remained effectively unchanged, at 16.49x.
- The Net Profit Margin for Camurus remained effectively unchanged, at 54.67%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.